Journal of Preventive Medicine and Public Health

  • 제57권5호
  • /
  • Pages.490-498
  • /
  • 2024
  • /
  • 1975-8375(pISSN)
  • /
  • 2233-4521(eISSN)
대한예방의학회 (The Korean Society for Preventive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Factors Associated With Coverage in Community-directed Treatment With Ivermectin for Onchocerciasis Control in Savanah and Forest Areas in Central African Republic: A Cross-sectional Study

  • Sylvain Honore Woromogo (Doctoral School of Human and Veterinary Sciences, University of Bangui) ;
  • Stephanie Inesse Garoua-Adjou (Doctoral School of Human and Veterinary Sciences, University of Bangui) ;
  • Ange Donatien Ngouyombo (Doctoral School of Human and Veterinary Sciences, University of Bangui) ;
  • Rodrigue Herman Doyama-Woza (Department of Public Health, Faculty of Health Sciences, University of Bangui) ;
  • Henri Saint Calvaire Diemer (Department of Public Health, Faculty of Health Sciences, University of Bangui) ;
  • Jean de Dieu Longo (Department of Public Health, Faculty of Health Sciences, University of Bangui)
  • 투고 : 2024.06.07
  • 심사 : 2024.08.01
  • 발행 : 2024.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: The aim of this study was to identify factors associated with coverage in community-directed treatment with ivermectin for onchocerciasis control in savannah and forest areas in the Central African Republic. Methods: A cross-sectional study was conducted in 2 districts where onchocerciasis is endemic. We employed a pretested and validated questionnaire that included questions about the socio-demographic characteristics of the respondents and variables relevant to coverage assessment. Multivariate logistic regression analyses were performed to identify the associations between surveyed mass drug administration (MDA) coverage and the variables considered, while accounting for potential confounding factors. A p-value <0.05 was considered statistically significant. Results: At the district level, the MDA program achieved a reach of 87.29% (95% confidence interval [CI], 86.03 to 88.55) in Bossangoa and 61.74% (95% CI, 59.56 to 63.92) in Kemo, compared to the reported rates of 90.02% and 91.70%, respectively. Women in both Bossangoa and Kemo were 1.28 times more likely to have taken ivermectin than men (95% CI, 1.12 to 1.47; p=0.008; 95% CI, 1.09 to 2.00; p=0.041, respectively). The age groups of 5-14, 15-24, and 25-34 were statistically associated with better distribution coverage in both districts. Individuals with knowledge of onchocerciasis were more likely to receive ivermectin compared to those without knowledge, with adjusted odds ratios of 1.41 (95% CI, 1.11 to 2.01; p=0.030) and 3.19 (95% CI, 2.91 to 4.08; p=0.001), respectively. Conclusions: The authors recommend implementing measures to improve MDA coverage in future campaigns. These measures should include allocating sufficient time for MDA activities, providing health education, and mobilising the entire population.

키워드

과제정보

We are thankful to the administrative and health districts of Bossangoa and Kemo, the village leaders, and. the residents of the studied communities for their cooperation. We are also grateful to the Ministry of Public Health and Population of Central African Republic for allowing this study.

참고문헌

  1. Mackenzie CD, Homeida MM, Hopkins AD, Lawrence JC. Elimination of onchocerciasis from Africa: possible? Trends Parasitol 2012;28(1):16-22. https://doi.org/10.1016/j.pt.2011.10.003
  2. Tada I. 3) Onchocerciasis. Trop Med Health 2015;43(Suppl):57-60. https://doi.org/10.2149/tmh.2015-S10
  3. World Health Organization. Onchocerciasis (river blindness) [cited 2024 Mar 12]. Available from: https://www.who.int/health-topics/onchocerciasis
  4. Benton B. Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview. Ann Trop Med Parasitol 1998;92 Suppl 1:S33-S39. https://doi.org/10.1080/00034989859537
  5. Molyneux DH. Onchocerciasis control and elimination: coming of age in resource-constrained health systems. Trends Parasitol 2005;21(11):525-529. https://doi.org/10.1016/j.pt.2005.08.027
  6. Babalola OE. Ocular onchocerciasis: current management and future prospects. Clin Ophthalmol 2011;5:1479-1491. https://doi.org/10.2147/OPTH.S8372
  7. Tekle AH, Zoure HG, Noma M, Boussinesq M, Coffeng LE, Stolk WA, et al. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infect Dis Poverty 2016;5(1):66. https://doi.org/10.1186/s40249-016-0160-7
  8. Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009;3(7):e497. https://doi.org/10.1371/journal.pntd.0000497
  9. Katabarwa MN, Griswold E, Habomugisha P, Eyamba A, Byamukama E, Nwane P, et al. Comparison of reported and survey-based coverage in onchocerciasis programs over a period of 8 years in Cameroon and Uganda. Am J Trop Med Hyg 2019;100(5):1208-1215. https://doi.org/10.4269/ajtmh.18-0680
  10. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, Doumbia K, et al. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis 2012;6(9):e1825. https://doi.org/10.1371/journal.pntd.0001825
  11. World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases - a roadmap for implementation; 2012 [cited 2024 May 26]. Available from: https://www.who.int/publications/i/item/WHO-HTM-NTD-2012.1
  12. World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected diseases; 2013 [cited 2024 May 26]. Available from: https://iris.who.int/handle/10665/77950
  13. Kuesel AC. Research for new drugs for elimination of onchocerciasis in Africa. Int J Parasitol Drugs Drug Resist 2016;6(3):272-286. https://doi.org/10.1016/j.ijpddr.2016.04.002
  14. Gebrezgabiher G, Yewhalaw D, Hailu A, Mekonnen Z. Evaluation of mass treatment with ivermectin program reach and survey coverage for onchocerciasis elimination in selected endemic areas of Ethiopia. PLoS One 2022;17(7):e0271518. https://doi.org/10.1371/journal.pone.0271518
  15. Stolk WA, Walker M, Coffeng LE, Basanez MG, de Vlas SJ. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis. Parasit Vectors 2015;8:552. https://doi.org/10.1186/s13071-015-1159-9
  16. Budge PJ, Sognikin E, Akosa A, Mathieu EM, Deming M. Accuracy of coverage survey recall following an integrated mass drug administration for lymphatic filariasis, schistosomiasis, and soil-transmitted helminthiasis. PLoS Negl Trop Dis 2016;10(1):e0004358. https://doi.org/10.1371/journal.pntd.0004358
  17. Griswold E, Eigege A, Ityonzughul C, Emukah E, Miri ES, Anagbogu I, et al. Evaluation of treatment coverage and enhanced mass drug administration for onchocerciasis and lymphatic filariasis in five local government areas treating twice per year in Edo State, Nigeria. Am J Trop Med Hyg 2018;99(2):396-403. https://doi.org/10.4269/ajtmh.17-1004
  18. Higazi TB, Geary TG, Mackenzie CD. Chemotherapy in the treatment, control, and elimination of human onchocerciasis. Res Rep Trop Med 2014;5:77-93. https://doi.org/10.2147/RRTM.S36642
  19. Baker MC, Krotki K, Sankara DP, Trofimovich L, Zoerhoff KL, Courtney L, et al. Measuring treatment coverage for neglected tropical disease control programs: analysis of a survey design. Am J Epidemiol 2013;178(2):268-275. https://doi.org/10.1093/aje/kws468
  20. Woodhall DM, Mkwanda S, Dembele M, Lwanga H, Drexler N, Dubray C, et al. Exploring innovative ways to conduct coverage surveys for neglected tropical diseases in Malawi, Mali, and Uganda. Acta Trop 2014;132:119-124. https://doi.org/10.1016/j.actatropica.2014.01.001
  21. Worrell C, Mathieu E. Drug coverage surveys for neglected tropical diseases: 10 years of field experience. Am J Trop Med Hyg 2012;87(2):216-222. https://doi.org/10.4269/ajtmh.2012.12-0167
  22. Zoure HG, Noma M, Tekle AH, Amazigo UV, Diggle PJ, Giorgi E, et al. The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected. Parasit Vectors 2014;7:326. https://doi.org/10.1186/1756-3305-7-326
  23. Uniting.Combat. Uniting to combat neglected tropical diseases (NTDs) [cited 2024 Mar 12]. Available from: https://unitingtocombatntds.org/en/
  24. World Health Organization. Preventive chemotherapy: tools for improving the quality of reported data and information: a field manual for implementation; 2019 [cited 2024 May 27]. Available from: https://www.who.int/publications/i/item/9789241516464
  25. World Health Organization. Independent participatory monitoring of CDTI projects: guidelines and instruments; 2002 [cited 2024 May 27]. Available from: https://iris.who.int/handle/10665/370265?locale-attribute=ru&
  26. World Health Organization. Elimination of human onchocerciasis: progress report, 2022-2023; 2023 [cited 2024 May 29]. Available from: https://www.who.int/publications/i/item/who-wer9845-572-582
  27. Semiyaga NB, Lalobo O, Ndyomugyenyi R. Refusal to take ivermectin: the associated 'risk' factors in Hoima district, Uganda. Ann Trop Med Parasitol 2005;99(2):165-172. https://doi.org/10.1179/136485905X24201
  28. Gebrezgabiher G, Yewhalaw D, Hailu A, Mekonnen Z. Evaluation of mass treatment with ivermectin program reach and survey coverage for onchocerciasis elimination in selected endemic areas of Ethiopia. PLoS One 2022;17(7):e0271518. https://doi.org/10.1371/journal.pone.0271518
  29. Serme M, Zida A, Bougma R, Kima A, Nassa C, Ouedraogo M, et al. Evaluation of therapeutic coverage of mass treatment campaign against lymphatic filariasis in two health districts in Burkina Faso. Med Trop Sante Int 2022;2(4):mtsi.v2i4.2022.174 (French). https://doi.org/10.48327/mtsi.v2i4.2022.174
  30. Gass K, Deming M, Bougma R, Drabo F, Tukahebwa EM, Mkwanda S, et al. A multicountry comparison of three coverage evaluation survey sampling methodologies for neglected tropical diseases. Am J Trop Med Hyg 2020;103(4):1700-1710. https://doi.org/10.4269/ajtmh.19-0946
  31. Brieger WR, Okeibunor JC, Abiose AO, Wanji S, Elhassan E, Ndyomugyenyi R, et al. Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria. Parasit Vectors 2011;4:152. https://doi.org/10.1186/1756-3305-4-152
  32. Onowhakpor AO, Okojie OH, Wagbatsoma VA. Assessment of the performance of community-directed treatment with ivermectin strategy for the control and elimination of onchocerciasis in Edo State, Nigeria. Indian J Public Health 2017;61(4):267-273. https://doi.org/10.4103/ijph.IJPH_236_16
  33. Lakwo TL, Gasarasi DB. Non-adherence to community directed treatment with ivermectin for onchocerciasis control in Rungwe district, southwest Tanzania. East Afr Med J 2006;83(6):326-332. https://doi.org/10.4314/eamj.v83i6.9440
  34. Griswold E, Eigege A, Ityonzughul C, Emukah E, Miri ES, Anagbogu I, et al. Evaluation of treatment coverage and enhanced mass drug administration for onchocerciasis and lymphatic filariasis in five local government areas treating twice per year in Edo State, Nigeria. Am J Trop Med Hyg 2018;99(2):396-403. https://doi.org/10.4269/ajtmh.17-1004
  35. Astale T, Sata E, Zerihun M, Nute AW, Stewart AE, Gessese D, et al. Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia. PLoS Negl Trop Dis 2018;12(2):e0006270. https://doi.org/10.1371/journal.pntd.0006270
  36. Churko C, Yihune M, Teshome A, Chisha Y, Getachew B, Sleshi M, et al. Ivermectin treatment coverage validation in two onchocerciasis endemic districts in Ethiopia: a community-based cross-sectional study, 2019. J Multidiscip Healthc 2021;14:137-144. https://doi.org/10.2147/JMDH.S288239
  37. Afonne C, Danso-Appiah A, Offor S, Ajayi I. A coverage evaluation survey for mass drug administration of ivermectin in Ukwa East local government area, Abia State, Nigeria. Int J Infect Dis 2020;101(Suppl 1):213. https://doi.org/10.1016/j.ijid.2020.09.566
  38. Yirga D, Deribe K, Woldemichael K, Wondafrash M, Kassahun W. Factors associated with compliance with community directed treatment with ivermectin for onchocerciasis control in Southwestern Ethiopia. Parasit Vectors 2010;3:48. https://doi.org/10.1186/1756-3305-3-48
  39. Amazigo UV, Obono M, Dadzie KY, Remme J, Jiya J, Ndyomugyenyi R, et al. Monitoring community-directed treatment programmes for sustainability: lessons from the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol 2002;96 Suppl 1:S75-S92. https://doi.org/10.1179/000349802125000664